ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

SS-31 (Elamipretide)

SS-31 (Elamipretide)

Also known as: Elamipretide, MTP-131, Bendavia, NAD+ Precursor Peptide

Overview

Key Facts

Primary Goal: Research and therapeutic applications of SS-31 (Elamipretide)

Binds cardiolipin in the inner mitochondrial membrane to stabilize electron transport complexes. Reduces mitochondrial reactive oxygen species (ROS) production.

Dosing Information

Half-Life

~4 hours

Typical Dose

0.25–4 mg

Frequency

Once daily

Cycle Length

4-12 weeks as studied in clinical trials

Administration Routes:
subcutaneousintravenous

Benefits

  • Restores mitochondrial function and energy production
  • Reduces oxidative stress at the mitochondrial level
  • Improves cardiac and skeletal muscle performance
  • Protects against age-related cellular decline
  • Supports kidney function in mitochondrial diseases

Side Effects

Injection site reactionsmild
Headachemild
Potential transient changes in renal markersmild
Nausea (uncommon)mild

Mechanism of Action

1

Binds cardiolipin in the inner mitochondrial membrane to stabilize electron transport complexes

2

Reduces mitochondrial reactive oxygen species (ROS) production

3

Restores ATP synthesis and mitochondrial membrane potential

4

Prevents cardiolipin peroxidation to maintain cristae structure

Contraindications

Do not use this peptide if any of the following apply:

  • Severe renal impairment (use with monitoring)
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptide components

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

Developed by Stealth BioTherapeutics, elamipretide has been evaluated in multiple Phase 2 and 3 clinical trials. The TAZPOWER trial in Barth syndrome showed improvements in six-minute walk test distance. Studies in primary mitochondrial myopathy (MMPOWER) and heart failure (PROGRESS-HF) have shown mixed results, though biomarker improvements were noted. Preclinical data strongly support mitochondrial protection against age-related decline, ischemia-reperfusion injury, and neurodegenerative conditions.

Frequently Asked Questions

Common questions about SS-31 (Elamipretide)

UK-Specific Information

Exclusive data points and guidance for UK residents using SS-31 (Elamipretide)

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok